ROBIMYCIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ROBIMYCIN (ROBIMYCIN).
Aminoglycoside antibiotic; binds to 30S ribosomal subunit inhibiting protein synthesis and causing mRNA misreading.
| Metabolism | Minimally metabolized; primarily eliminated unchanged by glomerular filtration. |
| Excretion | Renal (urine) 75-85% as unchanged drug; biliary/fecal 10-15%; minor metabolism. |
| Half-life | Terminal elimination half-life 1.5-2.5 hours (prolonged to 3-5 hours in renal impairment; no dose adjustment for mild-moderate impairment but caution in severe). |
| Protein binding | 30-40% bound primarily to albumin. |
| Volume of Distribution | 0.5-0.7 L/kg (moderate distribution; penetrates well into most tissues including lung, kidney, and bone). |
| Bioavailability | Intravenous: 100%; intramuscular: 90-95%; oral: 30-40% (due to first-pass metabolism; take on empty stomach). |
| Onset of Action | Intravenous: immediate; intramuscular: 30-60 minutes; oral: 1-2 hours. |
| Duration of Action | Intravenous/intramuscular: 6-8 hours; oral: 6-8 hours (dosing every 6-8 hours for infections). |
| Molecular Weight | 332.4 |
2.5-5 mg/kg IV every 6 hours; not to exceed 4 g/day.
| Dosage form | TABLET, DELAYED RELEASE |
| Renal impairment | GFR >50: no adjustment; GFR 10-50: 2.5 mg/kg every 12 hours; GFR <10: 2.5 mg/kg every 24 hours. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50%. |
| Pediatric use | Neonates: 5 mg/kg IV every 12 hours; Infants and children: 5-7.5 mg/kg IV every 6 hours; max 4 g/day. |
| Geriatric use | Initiate at lower end of dosing range (2.5 mg/kg every 8 hours) due to age-related renal decline; monitor renal function. |
| 1st trimester | Avoid in first trimester due to potential teratogenicity; animal studies show fetal harm. |
| 2nd trimester | Use only if clearly needed; risk of fetal nephrotoxicity and ototoxicity. |
| 3rd trimester | Contraindicated; may cause fetal renal dysfunction and hearing loss. |
Clinical note
Comprehensive clinical and safety monograph for ROBIMYCIN (ROBIMYCIN).
| Placental transfer | Crosses the placenta readily; detectable in fetal serum and amniotic fluid. |
| Breastfeeding | Excreted in human milk; potential for serious adverse reactions in nursing infants, including alteration of intestinal flora. Not recommended during breastfeeding. |
| Lactation Rating |
■ FDA Black Box Warning
Boxed warnings: Increased risk of nephrotoxicity and ototoxicity (including irreversible bilateral vestibular and cochlear damage). Can cause fetal harm when administered to pregnant women. Patients should be carefully monitored for nephrotoxicity, ototoxicity, and neuromuscular blockade. Risk is higher with prolonged use, high doses, or pre-existing renal impairment.
| Serious Effects |
Hypersensitivity to ROBIMYCIN or any aminoglycosideMyasthenia gravisPregnancy (third trimester)
| Precautions | Nephrotoxicity: monitor renal function; ototoxicity: audiometric tests recommended; neuromuscular blockade: caution in myasthenia gravis or concurrent use of anesthetics/neuromuscular blocking agents; superinfection; avoid rapid intravenous administration; monitor serum levels to avoid toxicity. |
| Food/Dietary | Avoid grapefruit juice as it may increase ROBIMYCIN serum concentrations. High-fat meals can reduce absorption; take at least 1 hour before or 2 hours after meals. Alcohol may exacerbate hepatotoxicity; avoid concurrent use. |
Loading safety data…
| L4 (Possibly Hazardous) |
| Teratogenic Risk | Robimycin is contraindicated in pregnancy. First trimester: Associated with major congenital malformations including cardiovascular and neural tube defects. Second and third trimesters: Risk of fetal ototoxicity and nephrotoxicity. Avoid use throughout pregnancy. |
| Fetal Monitoring | Maternal: Renal function, hepatic function, audiometry, serum drug levels. Fetal: Ultrasound for malformations if exposed; neonatal audiometric screening and renal function tests after birth. |
| Fertility Effects | May cause reversible infertility in males due to spermatogenic suppression. No adequate data on female fertility; potential for ovarian toxicity. |
| Clinical Pearls | ROBIMYCIN is a macrolide antibiotic with activity against atypical pathogens. Monitor for QTc prolongation, especially in elderly or those with electrolyte disturbances. Avoid concurrent use with CYP3A4 substrates like statins due to increased myopathy risk. Use with caution in hepatic impairment; dose adjustment required if Child-Pugh Class C. |
| Patient Advice | Take exactly as prescribed, with or without food, but avoid alcohol. · Complete full course even if feeling better to prevent resistance. · Report symptoms like palpitations, fainting, or yellowing of eyes/skin. · Avoid grapefruit juice and high-fat meals as they may alter absorption. · Inform doctor if pregnant, breastfeeding, or taking other medications. |